Psylutions and the DEA
In August 2025, the psychedelics movement crossed an unprecedented threshold. The U.S. Drug Enforcement Administration (DEA) announced that it would forward a petition to reschedule psilocybin, the psychoactive compound found in “magic mushrooms”, to the Department of Health and Human Services (HHS) for scientific review. The post Psylutions and the DEA appeared first on Microdose.
External link. We are not responsible for the content.
Read more ↗More From Microdose (industry)
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that...
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
A new data release from Enveric Biosciences is sharpening the scientific debate at the heart of psychedelic drug deve...
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanat...
Latest News
Where Does the World Go to Dance? Probs These EDM Festivals
A global guide to the festivals worth planning for. [...] Read More... The post Where Does the World Go to Dance? Pro...
Inclius Alvarious’s Place Within Indigenous Society
A look at Sonoran Desert toad medicine through the lens of indigenous sovereignty, ecological strain, and the debate ...
Can you kill a bad trip?: 5 Questions for emergency physician Gregory Yates
Yates discusses experimental attempts to end a psychedelic trip early.
Psychedelic Faeries Take on Prohibition and Authoritarianism
Plus psychedelics and telepathy, ego death for the rich, and our brain on Chat GPT [...] Read More... The post Psyche...
Introduction to Trip Sitting
The Art and Science of Holding Psychedelic Space
Heartbreak is a Bad Trip
Oli Genn-Bash describes how the aftermath of a sudden breakup felt like a prolonged ‘bad trip’, as well as the potent...